---
document_datetime: 2025-12-29 07:36:06
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zebinix.html
document_name: zebinix.html
version: success
processing_time: 0.1253789
conversion_datetime: 2025-12-30 02:04:55.539784
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zebinix

[RSS](/en/individual-human-medicine.xml/65931)

##### Authorised

This medicine is authorised for use in the European Union

eslicarbazepine acetate Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zebinix](#news-on)
- [More information on Zebinix](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Zebinix is an epilepsy medicine used to treat adults with partial-onset seizures (epileptic fits) with or without secondary generalisation. This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness or a sudden sense of fear. Secondary generalisation occurs when the overactivity later reaches the whole brain. Zebinix can be taken on its own, in newly diagnosed epilepsy, or can be added to existing antiepileptic medicines.

Zebinix can also be used in adolescents and children above 6 years of age, in combination with existing therapies, to treat partial-onset seizures with or without secondary generalisation.

Zebinix contains the active substance eslicarbazepine acetate.

Expand section

Collapse section

## How is Zebinix used?

Zebinix can only be obtained with a prescription. It is available as tablets (200 mg, 400 mg, 600 mg and 800 mg) and as a suspension to be taken by mouth.

For adults and children weighing 60 kg or more, treatment is started at a dose of 400 mg once a day, before increasing it to the standard dose of 800 mg once a day after one or two weeks. In children weighing less than 60 kg, the starting dose is 10 mg per kg body weight once a day. The dose is then increased after one or two weeks to 20 mg/kg per day and then to 30 mg/kg per day, based on the patient's response. For adults who take Zebinix on its own, a dose up to 1,600 mg may be used. For children and adults who use Zebinix in combination with other medicines the maximum dose is 1,200 mg once a day.

Zebinix should not be used in patients with severe kidney problems and the dose should be adjusted in moderately impaired kidney function.

For more information about using Zebinix, see the package leaflet or contact your doctor or pharmacist.

## How does Zebinix work?

The active substance in Zebinix, eslicarbazepine acetate, is converted into eslicarbazepine in the body. Epilepsy is caused by excessive electrical activity in the brain. For electrical impulses to travel along nerves there needs to be a rapid movement of sodium into the nerve cells. Eslicarbazepine is thought to work by blocking 'voltage-gated sodium channels', which stops sodium entering the nerve cells. This reduces the activity of the nerve cells in the brain, reducing the intensity and the number of seizures.

## What benefit of Zebinix have been shown in studies?

Three main studies compared Zebinix with placebo (a dummy treatment) in 1,050 adults with partial-onset seizures that were not controlled by other medicines. All of the patients also received other epilepsy medicines. Looking at the results of the three studies taken together, Zebinix 800 mg and 1,200 mg were more effective than placebo at reducing the number of seizures, when used as add-on to other epilepsy medicines. At the start of the study, patients had around 13 seizures per month. Over the 12 weeks of treatment, this fell to 9.8 and 9.0 seizures per month in patients taking Zebinix 800 mg and Zebinix 1,200 mg respectively, compared with 11.7 per month in those taking placebo.

Another study compared Zebinix taken on its own with another epilepsy medicine, carbamazepine, in 815 newly diagnosed adults. Zebinix was effective, although slightly less than carbamazepine, at reducing seizures after 6 months of treatment: 71% of patients who took Zebinix and did not prematurely withdraw from the study (276 out of 388 patients) were seizure-free after 6 months compared with 76% of patients taking carbamazepine (300 out of 397 patients).

The effects of Zebinix were also studied in children with partial-onset seizures. In these studies, all the children also received other epilepsy medicines. In one study involving 123 children aged 6 to 16 years, Zebinix over 12 weeks halved the number of seizures in 51% of patients (42 out of 83). This compared with 25% of patients (10 out of 40) on placebo. A second study in children aged 2 to 18 years did not find a difference between Zebinix and placebo, this was explained by the fact that lower doses were used.

## What are the risks associated with Zebinix?

In clinical trials, around half of the patients treated with Zebinix experienced side effects. Side effects were usually mild to moderate in intensity and occurred mostly in the first week of treatment. For adults, the most common side effects with Zebinix (seen in more than 1 patient in 10) are dizziness, somnolence (sleepiness), headache and nausea. Severe skin reactions, including Stevens-Johnson syndrome, have also been reported with Zebinix.

Zebinix must not be used in people who are hypersensitive (allergic) to eslicarbazepine acetate, any of the other ingredients or other carboxamide derivatives (medicines with a similar structure to eslicarbazepine acetate, such as carbamazepine or oxcarbazepine). It must not be used in people with second or third degree atrioventricular block (a problem with electrical transmission in the heart).

For the full list of side effects and restrictions with Zebinix, see the package leaflet.

## Why is Zebinix authorised?

The European Medicines Agency decided that Zebinix's benefits are greater than its risks and that it be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Zebinix?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zebinix have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Zebinix are continuously monitored. Side effects reported with Zebinix are carefully evaluated and any necessary action taken to protect patients.

## Other information about Zebinix

Zebinix received a marketing authorisation valid throughout the EU on 21 April 2009.

Zebinix : EPAR - Summary for the public

English (EN) (110.57 KB - PDF)

**First published:** 20/05/2009

**Last updated:** 31/07/2018

[View](/en/documents/overview/zebinix-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-28)

български (BG) (105.29 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/bg/documents/overview/zebinix-epar-summary-public_bg.pdf)

español (ES) (77.94 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/es/documents/overview/zebinix-epar-summary-public_es.pdf)

čeština (CS) (103.61 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/cs/documents/overview/zebinix-epar-summary-public_cs.pdf)

dansk (DA) (76.7 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/da/documents/overview/zebinix-epar-summary-public_da.pdf)

Deutsch (DE) (78.57 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/de/documents/overview/zebinix-epar-summary-public_de.pdf)

eesti keel (ET) (76.63 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/et/documents/overview/zebinix-epar-summary-public_et.pdf)

ελληνικά (EL) (104.21 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/el/documents/overview/zebinix-epar-summary-public_el.pdf)

français (FR) (78.17 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/fr/documents/overview/zebinix-epar-summary-public_fr.pdf)

hrvatski (HR) (98.11 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/hr/documents/overview/zebinix-epar-summary-public_hr.pdf)

italiano (IT) (77.15 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/it/documents/overview/zebinix-epar-summary-public_it.pdf)

latviešu valoda (LV) (101.57 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/lv/documents/overview/zebinix-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (102.76 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/lt/documents/overview/zebinix-epar-summary-public_lt.pdf)

magyar (HU) (100.16 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/hu/documents/overview/zebinix-epar-summary-public_hu.pdf)

Malti (MT) (98.46 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/mt/documents/overview/zebinix-epar-summary-public_mt.pdf)

Nederlands (NL) (76.97 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/nl/documents/overview/zebinix-epar-summary-public_nl.pdf)

polski (PL) (104.87 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/pl/documents/overview/zebinix-epar-summary-public_pl.pdf)

português (PT) (77.48 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/pt/documents/overview/zebinix-epar-summary-public_pt.pdf)

română (RO) (102.09 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/ro/documents/overview/zebinix-epar-summary-public_ro.pdf)

slovenčina (SK) (101.71 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/sk/documents/overview/zebinix-epar-summary-public_sk.pdf)

slovenščina (SL) (98.56 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/sl/documents/overview/zebinix-epar-summary-public_sl.pdf)

Suomi (FI) (76.84 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/fi/documents/overview/zebinix-epar-summary-public_fi.pdf)

svenska (SV) (77.11 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

31/07/2018

[View](/sv/documents/overview/zebinix-epar-summary-public_sv.pdf)

## Product information

Zebinix : EPAR - Product Information

English (EN) (1.28 MB - PDF)

**First published:** 27/05/2009

**Last updated:** 31/03/2025

[View](/en/documents/product-information/zebinix-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-606)

български (BG) (1.69 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/bg/documents/product-information/zebinix-epar-product-information_bg.pdf)

español (ES) (1.34 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/es/documents/product-information/zebinix-epar-product-information_es.pdf)

čeština (CS) (1.43 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/cs/documents/product-information/zebinix-epar-product-information_cs.pdf)

dansk (DA) (1.25 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/da/documents/product-information/zebinix-epar-product-information_da.pdf)

Deutsch (DE) (1.4 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/de/documents/product-information/zebinix-epar-product-information_de.pdf)

eesti keel (ET) (1.26 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/et/documents/product-information/zebinix-epar-product-information_et.pdf)

ελληνικά (EL) (1.65 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/el/documents/product-information/zebinix-epar-product-information_el.pdf)

français (FR) (1.38 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/fr/documents/product-information/zebinix-epar-product-information_fr.pdf)

hrvatski (HR) (1.47 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/hr/documents/product-information/zebinix-epar-product-information_hr.pdf)

íslenska (IS) (1.27 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/is/documents/product-information/zebinix-epar-product-information_is.pdf)

italiano (IT) (1.38 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/it/documents/product-information/zebinix-epar-product-information_it.pdf)

latviešu valoda (LV) (1.4 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/lv/documents/product-information/zebinix-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.4 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/lt/documents/product-information/zebinix-epar-product-information_lt.pdf)

magyar (HU) (1.58 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/hu/documents/product-information/zebinix-epar-product-information_hu.pdf)

Malti (MT) (1.82 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/mt/documents/product-information/zebinix-epar-product-information_mt.pdf)

Nederlands (NL) (1.34 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/nl/documents/product-information/zebinix-epar-product-information_nl.pdf)

norsk (NO) (1.38 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/no/documents/product-information/zebinix-epar-product-information_no.pdf)

polski (PL) (1.7 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/pl/documents/product-information/zebinix-epar-product-information_pl.pdf)

português (PT) (1.24 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/pt/documents/product-information/zebinix-epar-product-information_pt.pdf)

română (RO) (1.52 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/ro/documents/product-information/zebinix-epar-product-information_ro.pdf)

slovenčina (SK) (1.41 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/sk/documents/product-information/zebinix-epar-product-information_sk.pdf)

slovenščina (SL) (1.4 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/sl/documents/product-information/zebinix-epar-product-information_sl.pdf)

Suomi (FI) (1.33 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/fi/documents/product-information/zebinix-epar-product-information_fi.pdf)

svenska (SV) (1.25 MB - PDF)

**First published:**

27/05/2009

**Last updated:**

31/03/2025

[View](/sv/documents/product-information/zebinix-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000261032 31/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zebinix : EPAR - All Authorised presentations

English (EN) (137.69 KB - PDF)

**First published:** 20/05/2009

**Last updated:** 29/09/2017

[View](/en/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-349)

български (BG) (119.65 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/bg/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_bg.pdf)

español (ES) (111.23 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/es/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_es.pdf)

čeština (CS) (115.95 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/cs/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (112.18 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/da/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (114.74 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/de/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (108.18 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/et/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (187.29 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/el/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_el.pdf)

français (FR) (111.64 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/fr/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (111.09 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/hr/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (112.3 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/is/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_is.pdf)

italiano (IT) (109.51 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/it/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (114.02 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/lv/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (114.54 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/lt/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (117.63 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/hu/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (115.35 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/mt/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (109.18 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/nl/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (112.06 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/no/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_no.pdf)

polski (PL) (112.4 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/pl/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_pl.pdf)

português (PT) (115.55 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/pt/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_pt.pdf)

română (RO) (113.38 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/ro/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (115.63 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/sk/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (111.2 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/sl/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (109.36 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/fi/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (110.67 KB - PDF)

**First published:**

20/05/2009

**Last updated:**

29/09/2017

[View](/sv/documents/all-authorised-presentations/zebinix-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zebinix Active substance eslicarbazepine acetate International non-proprietary name (INN) or common name eslicarbazepine acetate Therapeutic area (MeSH) Epilepsy Anatomical therapeutic chemical (ATC) code N03AF04

### Pharmacotherapeutic group

Antiepileptics

### Therapeutic indication

Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.

## Authorisation details

EMA product number EMEA/H/C/000988 Marketing authorisation holder

BIAL - Portela &amp; Ca, S.A.

BIAL - Portela &amp; Ca, S.A.

Opinion adopted 19/02/2009 Marketing authorisation issued 21/04/2009 Revision 33

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zebinix : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (146.57 KB - PDF)

**First published:** 31/03/2025

**Last updated:** 06/08/2025

[View](/en/documents/procedural-steps-after/zebinix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Zebinix : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (280.59 KB - PDF)

**First published:** 27/05/2009

**Last updated:** 31/03/2025

[View](/en/documents/procedural-steps-after/zebinix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Zebinix-H-C-988-P46-026.1 : EPAR - Assessment report

Adopted

Reference Number: EMA/76302/2022

English (EN) (634.82 KB - PDF)

**First published:** 07/02/2022

[View](/en/documents/variation-report/zebinix-h-c-988-p46-0261-epar-assessment-report_en.pdf)

Zebinix-H-C-988-P46-026 : EPAR - Assessment report

Adopted

Reference Number: EMA/42324/2021

English (EN) (552.18 KB - PDF)

**First published:** 21/01/2021

[View](/en/documents/variation-report/zebinix-h-c-988-p46-026-epar-assessment-report_en.pdf)

Zebinix-PSUSA-00001267-201410 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/PRAC/613519/2019

English (EN) (117.13 KB - PDF)

**First published:** 12/11/2019

[View](/en/documents/scientific-conclusion/zebinix-psusa-00001267-201410-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf-0)

Zebinix-H-C-988-P46-025 : EPAR - Assessment report

Adopted

Reference Number: EMA/476835/2018

English (EN) (348.63 KB - PDF)

**First published:** 08/11/2018

[View](/en/documents/variation-report/zebinix-h-c-988-p46-025-epar-assessment-report_en.pdf)

Zebinix-H-C-988-II-0053 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/304195/2017

English (EN) (1.2 MB - PDF)

**First published:** 20/06/2017

**Last updated:** 20/06/2017

[View](/en/documents/variation-report/zebinix-h-c-988-ii-0053-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Zebinix

Adopted

Reference Number: EMA/CHMP/824232/2016

English (EN) (71.71 KB - PDF)

**First published:** 24/03/2017

**Last updated:** 24/03/2017

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zebinix_en.pdf)

Zebinix-H-C-988-X-0050-G : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/728128/2016

English (EN) (1.6 MB - PDF)

**First published:** 21/12/2016

**Last updated:** 21/12/2016

[View](/en/documents/variation-report/zebinix-h-c-988-x-0050-g-epar-assessment-report-extension_en.pdf)

CHMP post-authorisation summary of positive opinion for Zebinix

Adopted

Reference Number: EMA/CHMP/643479/2016

English (EN) (67.1 KB - PDF)

**First published:** 14/10/2016

**Last updated:** 14/10/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zebinix_en.pdf-0)

Zebinix-H-C-988-P46-024 : EPAR - Assessment Report

Adopted

Reference Number: EMA/432457/2016

English (EN) (126.44 KB - PDF)

**First published:** 21/06/2016

**Last updated:** 21/06/2016

[View](/en/documents/variation-report/zebinix-h-c-988-p46-024-epar-assessment-report_en.pdf)

Zebinix-PSUSA-00001267-201410 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/516204/2015

English (EN) (68.73 KB - PDF)

**First published:** 15/10/2015

**Last updated:** 15/10/2015

[View](/en/documents/scientific-conclusion/zebinix-psusa-00001267-201410-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Zebinix-H-C-988-P46-023.1 : EPAR - Assessment Report

Adopted

Reference Number: EMA/475393/2015

English (EN) (486.24 KB - PDF)

**First published:** 27/07/2015

**Last updated:** 27/07/2015

[View](/en/documents/variation-report/zebinix-h-c-988-p46-0231-epar-assessment-report_en.pdf)

Zebinix-H-C-988-P46-023 : EPAR - Assessment report

Adopted

Reference Number: EMA/414667/2014

English (EN) (211.42 KB - PDF)

**First published:** 01/08/2014

**Last updated:** 01/08/2014

[View](/en/documents/variation-report/zebinix-h-c-988-p46-023-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Zebinix : EPAR - Public assessment report

English (EN) (1.2 MB - PDF)

**First published:** 03/06/2009

**Last updated:** 03/06/2009

[View](/en/documents/assessment-report/zebinix-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use  summary of positive opinion  for Zebinix

English (EN) (76.41 KB - PDF)

**First published:** 19/02/2009

**Last updated:** 19/02/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-zebinix_en.pdf)

#### News on Zebinix

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 March 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-march-2017) 24/03/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2016) 14/10/2016

#### More information on Zebinix

- [EMEA-000696-PIP02-10-M08 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000696-pip02-10-m08)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Paediatrics](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A65)

**This page was last updated on** 06/08/2025

## Share this page

[Back to top](#main-content)